welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia
source: Cancer Prevention Research
year: 2017
authors: Don A. Delker, Austin C. Wood, Angela K. Snow, N. Jewel Samadder, Wade S. Samowitz, Kajsa E. Affolter, Kenneth M. Boucher, Lisa M. Pappas, Inge J. Stijleman, Priyanka Kanth , Kathryn R. Byrne, Randall W. Burt, Philip S. Bernard, Deborah W. Neklason
summary/abstract:Abstract
To identify gene expression biomarkers and pathways targeted by sulindac and erlotinib given in a chemoprevention trial with a significant decrease in duodenal polyp burden at 6 months (P < 0.001) in familial adenomatous polyposis (FAP) patients, we biopsied normal and polyp duodenal tissues from patients on drug versus placebo and analyzed the RNA expression. RNA sequencing was performed on biopsies from the duodenum of FAP patients obtained at baseline and 6-month endpoint endoscopy. Ten FAP patients on placebo and 10 on sulindac and erlotinib were selected for analysis. Purity of biopsied polyp tissue was calculated from RNA expression data. RNAs differentially expressed between endpoint polyp and paired baseline normal were determined for each group and mapped to biological pathways. Key genes in candidate pathways were further validated by quantitative RT-PCR. RNA expression analyses of endpoint polyp compared with paired baseline normal for patients on placebo and drug show that pathways activated in polyp growth and proliferation are blocked by this drug combination. Directly comparing polyp gene expression between patients on drug and placebo also identified innate immune response genes (IL12 and IFNg) preferentially expressed in patients on drug. Gene expression analyses from tissue obtained at endpoint of the trial demonstrated inhibition of the cancer pathways COX2/PGE2, EGFR, and WNT. These findings provide molecular evidence that the drug combination of sulindac and erlotinib reached the intended tissue and was on target for the predicted pathways. Furthermore, activation of innate immune pathways from patients on drug may have contributed to polyp regression.
DOI: 10.1158/1940-6207.CAPR-17-0130
read more
expertly curated content related to this topic
-
Desmoid Tumour in Familial Adenomatous Polyposis Patients: Responses to TreatmentsNo guidelines for desmoid tumors (DT) ma...
-
Clinical End Points for Developing Pharmaceuticals to Manage Patients with a Sporadic or Genetic Risk of Colorectal ...To reduce the morbidity and mortality fr...
-
Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Poly...The purpose of this study is to determin...
-
A Phase Ib Study of the Effects of Black Raspberries on Rectal Polyps in Patients With Familial Adenomatous Polyposi...Familial adenomatous polyposis (FAP) is ...
-
Endomicrocancer: Confocal Endomicroscopy in Patients With High Risk of Colorectal CancerThe principle objective of this study is...
-
The Ileo Neo Rectal Anastomosis: Long-term Results of Surgical Innovation in Patients After Ulcerative Colitis and F...PURPOSE: Restorative proctocolectomy wi...
-
Genetics, Inheritance and Strategies for Prevention in Populations at High Risk of Colorectal Cancer (CRC)Hereditary forms of colorectal cancer ac...